이상반응 보고
| VAERS ID | 2481906 |
|---|---|
| 성별 | 여성 |
| 나이 | 25세 |
| 주 코드 | IA |
| 제약회사 | PFIZER\BIONTECH |
| 로트 번호 | GH9702 |
| 예방접종 횟수 | 1 |
| 접종일 | 2022-10-17 |
| 발병일 | 2022-10-01 |
| 상태 |
증상
- 임신 중 노출(Exposure during pregnancy)
- 부작용 없음(No adverse event)
- 잘못된 제품 제형이 투여됨(Incorrect product formulation administered)
이환 중 질병
Pregnancy, headache
지병
Asthma, multiple environmental allergies.
기타 의료
Ferrous Sulfate, Ibuprofen, Fluticasone, Lansoprazole, Loratadine, Albuterol, Benralizumab, Budesonide formoterol and epinephrine
이전 예방접종
알레르기
NKMA
임상 검사
Pt to follow up as scheduled in 3 weeks for second covid vaccine - as noted by Pfizer - the second dose should be a Monovalent vaccine.
증상 상세
Provider ordered initial covid vaccine and patient received Bivalent Pfizer booster dose instead.
Employee notified manager.
Manager notified provider and pharmacist.
Information received from both Department of Public Health and Manufacture - "If a bivalent Pfizer-BioNtech vaccine is administered for primary series dose: Do not repeat the dose.
The primary and booster dosages are the same; the bivalent dose can be counted as a primary series dose.
Continue with the recommended vaccination schedule: (iel, complete the primary series with a monovalent Pfizer-BioNTech vaccine, then administer a bivalent booster dose at least 2 months after completion of the primary series.
" All information provided.
No adverse reactions noted.
No adverse reactions at this time.